RESPIRATORY SYNCYTIAL VIRUS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Moderna tests mRNA vaccines for four viruses in one study
⭐️ VACCINE ⭐️ CompletedThis study tested the safety and immune response of several modified mRNA vaccines in 308 healthy adults aged 18 to 75. The vaccines target SARS-CoV-2, seasonal influenza, respiratory syncytial virus, and cytomegalovirus. Researchers monitored side effects and measured antibody l…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 11:08 UTC
-
New RSV vaccine shows promise for older adults in korea
⭐️ VACCINE ⭐️ CompletedThis study tested a new RSV vaccine in 378 adults aged 60 and older in Korea. The goal was to see if the vaccine is safe and helps the body build defenses against RSV, a virus that can cause serious breathing problems. Participants received either the vaccine or a placebo and wer…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 22, 2026 14:02 UTC
-
New mRNA RSV vaccine shows promise for older adults in major trial
⭐️ VACCINE ⭐️ CompletedThis study tested an experimental mRNA vaccine (mRNA-1345) to protect against RSV, a virus that can cause serious lung infections in older adults. About 3,300 people aged 50 and older received the RSV vaccine alone, or at the same time as a flu or COVID-19 booster. Researchers ch…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 18, 2026 12:07 UTC
-
RSV booster study shows promise for older adults
⭐️ VACCINE ⭐️ CompletedThis study tested a booster dose of the experimental mRNA-1345 RSV vaccine in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least 12 months earlier. The goal was to see if the booster was safe and boosted the body's immune defenses against RSV. R…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:04 UTC
-
New shot shields thousands of babies from severe RSV
Prevention CompletedThis study tested how well a single dose of BEYFORTUS (nirsevimab) protects infants from serious RSV infections that require a doctor visit. Nearly 50,000 babies were followed during their first RSV season. The goal was to see if the shot reduces hospitalizations, emergency visit…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Prevention
Last updated May 26, 2026 11:26 UTC